Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA) Overall, 234 patients were randomly ...

With the aim of comparing the efficacy of cisplatin versus carboplatin in the first-line treatment of SCLC, we conducted a meta-analysis of individual patient data (COCIS; Carboplatin- or ...

Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of cisplatin ...

Cisplatin-based chemotherapy regimens provide a survival benefit for patients with advanced or metastatic urothelial carcinoma of the bladder. Clinicians should follow established criteria for ...

Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said. FDA Commissioner Robert ...

PEDMARQSI (sodium thiosulfate solution for infusion) becomes the first and only treatment authorised in Switzerland for the prevention of cisplatin-induced ototoxicity (hearing loss) in patients ...

Credit: Getty Images. The approval was based on data from 2 pivotal phase 3 trials, which evaluated Pedmark in pediatric patients undergoing treatment with cisplatin-based chemotherapy. The Food and ...

An ongoing shortage of cancer drug cisplatin just got longer. Drugmakers told the American Society of Health-System Pharmacists they expect their cisplatin supply to return to normal levels in June, ...

Credit: Getty Images. Pedmark is the first FDA-approved therapy indicated to reduce the risk of cisplatin-induced hearing loss in children. Pedmark ® (sodium thiosulfate) is now available to reduce ...